BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 18591381)

  • 1. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
    Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
    Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
    Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.
    Fujiwara H; El Ouriaghli F; Grube M; Price DA; Rezvani K; Gostick E; Sconocchia G; Melenhorst J; Hensel N; Douek DC; Barrett AJ
    Blood; 2004 Apr; 103(8):3076-83. PubMed ID: 15070688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
    Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
    Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
    Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
    Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.
    Ochi T; Fujiwara H; Suemori K; Azuma T; Yakushijin Y; Hato T; Kuzushima K; Yasukawa M
    Blood; 2009 Jan; 113(1):66-74. PubMed ID: 18820130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
    LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
    Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
    Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
    Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
    Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
    Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CML vaccines as a paradigm of the specific immunotherapy of cancer.
    Pinilla-Ibarz J; Cathcart K; Scheinberg DA
    Blood Rev; 2000 Jun; 14(2):111-20. PubMed ID: 11012250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
    Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
    Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells.
    Shao S; Risch E; Burner D; Lu L; Minev B; Ma W
    Int Immunopharmacol; 2017 Jun; 47():159-165. PubMed ID: 28410529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.
    Yong AS; Stephens N; Weber G; Li Y; Savani BN; Eniafe R; Keyvanfar K; Kurlander R; Rezvani K; Barrett AJ
    Leukemia; 2011 Apr; 25(4):629-37. PubMed ID: 21252986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
    Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
    Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.